Phosphorylation Activity Assay Services: Kinase Profiling & Phosphoprotein Analysis for Drug Discovery & Cell Signaling

As an independent third-party analytical service provider, we offer comprehensive phosphorylation activity testing for protein kinases, cellular signaling studies, drug screening, and biomarker validation. Protein phosphorylation – the reversible addition of a phosphate group to serine, threonine, or tyrosine residues – is one of the most critical post‑translational modifications regulating virtually all cellular processes, including proliferation, differentiation, apoptosis, metabolism, and immune responses. Dysregulation of kinase activity is implicated in cancer, inflammation, neurodegeneration, and metabolic diseases, making kinases a major class of drug targets. Our accredited laboratory follows established biochemical and cellular assay protocols (including radiometric, fluorescence‑based, mass spectrometry, and immunoassay platforms) to deliver accurate, reproducible, and actionable phosphorylation activity data. This article outlines our phosphorylation activity testing capabilities – including scope, key test items, and standard test methods – to help pharmaceutical companies, academic researchers, and biotechnology firms characterize kinase function, screen inhibitors, and validate phospho‑specific biomarkers.

1. Our Testing Scope for Phosphorylation Activity

We cover a broad range of kinase classes, sample types, and assay formats:

By kinase type / target family: Protein tyrosine kinases (PTKs) – receptor tyrosine kinases (EGFR, HER2, VEGFR, PDGFR, FGFR, c‑Met, Trk, ALK, ROS1, RET, etc.); non‑receptor tyrosine kinases (Src family – Src, Lyn, Fyn; Abl, Jak, FAK, Syk, Zap70, Tec family); Serine/threonine kinases (MAPKs – ERK1/2, p38, JNK; PI3K/Akt/mTOR pathway; CDKs – cyclin‑dependent kinases; PKC family; PKA, PKG, CaMK; GSK3β; AMPK; Aurora kinases; Chk1/2; IKK complex); Dual‑specificity kinases (MEK, MKK, CLK, DYRK); Atypical kinases (PIKK family – ATM, ATR, DNA‑PK, mTOR).

By sample matrix / source: Purified recombinant kinases (full‑length or truncated); Immunoprecipitated kinases from cell lysates; Cell lysates (total protein extracts, subcellular fractions – nuclear, cytoplasmic, membrane); Tissue homogenates (tumor biopsies, mouse xenografts, brain tissue, liver, heart, etc.); Whole blood and peripheral blood mononuclear cells (PBMCs); Formalin‑fixed, paraffin‑embedded (FFPE) tissue sections – after optimization; Phosphopeptide substrate and synthetic peptide libraries.

By assay type / measurement mode: Biochemical kinase activity assays – measure the ability of a purified kinase to transfer the γ‑phosphate of ATP to a substrate peptide or protein. Detection methods include radiometric (³³P‑ATP or ³²P‑ATP, traditional gold standard), fluorescence‑based (IMAP, Transcreener, Z’-LYTE, Adapta, HotSpot), luminescence (ADP‑Glo, Kinase‑Glo), and mass spectrometry (LC‑MS/MS – label‑free). Cellular phosphorylation assays – measure the phosphorylation status of specific signaling proteins within living cells or lysates after stimulation (e.g., EGF, insulin, LPS) or drug treatment. Techniques include Western blot (phospho‑specific antibodies), bead‑based multiplex assays (Luminex xMAP), ELISA (phosphoprotein ELISAs, sandwich format), flow cytometry (phospho‑flow, intracellular staining), immunofluorescence (IF) for subcellular localization, and proximity ligation assay (PLA) to detect in situ phosphorylation.

By end‑user / application: Drug discovery and development – kinase inhibitor screening (IC₅₀, Kᵢ determination, selectivity profiling, potency ranking); hit identification (primary screening of compound libraries) and lead optimization; Mechanism of action (MoA) studies – elucidating downstream signaling pathways affected by a compound; Biomarker development – validation of phosphoproteins as pharmacodynamic (PD) biomarkers (e.g., p‑ERK, p‑AKT, p‑S6RP) or predictive biomarkers (e.g., EGFR phosphorylation status for cetuximab response); Basic cell signaling research – mapping kinase‑substrate networks, identifying phosphorylation sites, and characterizing crosstalk between pathways.

By industry / regulatory compliance: Preclinical pharmacology studies; IND‑enabling MoA support; Clinical trial biomarker analysis; GLP‑compliant studies (by arrangement).

2. Key Test Items & Measurements We Perform

Our phosphorylation activity testing services are organized into three categories: biochemical kinase assays, cellular phosphoprotein assays, and phospho‑site mapping/quantitation.

2.1 Biochemical Kinase Activity Assays (Purified Kinase, In Vitro)

These assays measure the catalytic activity of a purified kinase (wild‑type or mutant) using a defined substrate, ATP, and detection system.

Kinase inhibition profile (IC₅₀ and Kᵢ) – A series of inhibitor concentrations is incubated with the kinase, and the residual activity is measured. The IC₅₀ (half‑maximal inhibitory concentration) is calculated from the dose‑response curve. For reversible inhibitors, the inhibition constant Kᵢ (Cheng‑Prusoff equation) can also be derived. We test single‑point (e.g., 1 μM) for initial screening or full 10‑point curves for precise IC₅₀ determination.

Kinase selectivity profiling (panel screening) – We test a lead compound against a panel of 50‑500 diverse kinases (broad‑coverage selectivity panel). The % inhibition at a defined concentration (e.g., 1 μM or 10 μM) and/or IC₅₀ values for off‑target kinases are reported. This data helps de‑risk off‑target toxicity (e.g., hERG, cardiovascular, CNS, or endocrine liabilities) before advancing to animal studies.

Kinase enzymatic parameters (K_m for ATP and substrate, V_max, k_cat) – The Michaelis constant for ATP (K_m,ATP) and peptide substrate (K_m,pep) are determined by measuring initial rates at varying substrate concentrations. V_max and the turnover number k_cat are calculated from the fitted curves. These parameters aid in understanding the mechanism of action of kinase inhibitors (e.g., ATP‑competitive vs. non‑competitive, Type I, II, III inhibitors).

ATP‑competitive binding (K_i,app) – For compounds suspected to be ATP‑competitive, we perform IC₅₀ measurements at multiple ATP concentrations (e.g., 10, 100, 1000 μM). A rightward shift of the IC₅₀ with increasing ATP indicates ATP‑competitive behavior.

Substrate peptide mapping (peptide library screening) – For orphan kinases, we can identify optimal phosphorylation motifs by screening a panel of peptide substrates. The preferred consensus sequence (e.g., [KR]xx[S/T] for PKA, Yxx[ILV] for Src family) is derived.

Time‑course activity (progress curve) – For slow‑binding inhibitors, we measure product formation over time to calculate k_on/k_off rates and determine the type of inhibition (reversible or irreversible, covalent).

2.2 Cellular Phosphorylation Assays (Cell‑Based, In Vivo‑Like Context)

These assays measure the phosphorylation status of specific signaling proteins within live cells treated with test compounds, stimulants, or genetic perturbations. They are closer to physiological conditions and reveal drug efficacy in a complex cellular environment.

IC₅₀ for intracellular target engagement – After incubating cells with a range of inhibitor concentrations, the phosphorylation level of the direct substrate (e.g., p‑AKT for PI3K/mTOR inhibitors, p‑ERK for MEK inhibitors) is measured by Western blot, ELISA, or AlphaLISA. The cellular IC₅₀ (EC₅₀) is calculated; values within 10‑fold of the biochemical IC₅₀ suggest good cell permeability.

Time‑course phosphorylation (kinetics of activation/inhibition) – Cells are treated with a stimulant (e.g., EGF, insulin, PMA) or inhibitor, and samples are collected at multiple time points (0‑120 minutes). This reveals the dynamics of pathway activation/deactivation and is critical for determining optimal dosing schedules.

Pathway crosstalk analysis (phosphoprotein multiplexing) – Using bead‑based multiplex platforms (Luminex xMAP, Bio‑Plex Pro™ phospho‑protein panels) or high‑throughput Western (Simple Western), we simultaneously measure 5‑30 phosphoproteins (e.g., p‑AKT, p‑ERK, p‑S6RP, p‑GSK3β, p‑NF‑κB p65, p‑STAT3, p‑EGFR, p‑HER2, p‑c‑Raf, p‑MEK) from a single lysate sample. This reveals how an inhibitor blocks one pathway and may activate compensatory signaling (e.g., ERK reactivation, PI3K feedback).

Phospho‑flow cytometry – For heterogeneous cell populations (e.g., PBMCs, mixed tumor cells), we use flow cytometry with phospho‑specific antibodies to measure signaling activity at the single‑cell level. This technique identifies responder vs. non‑responder subsets and detects off‑target activation in specific immune cell lineages.

High‑content imaging (HCI) – Phosphorylation status is quantified by automated microscopy (e.g., Operetta, CellInsight). We detect p‑AKT, p‑ERK, p‑CREB, or histone H3 (pSer28, p‑H3, mitosis marker) with nuclear‑cytoplasmic translocation metrics. This is ideal for adherent cells and rare populations.

2.3 Phosphoproteomics & Phospho‑Site Mapping (Mass Spectrometry)

For discovery‑driven projects or detailed mechanistic studies, we employ LC‑MS/MS to identify and quantify phosphorylation sites on a global scale or on a specific target protein.

Global phosphoproteomics – Titanium dioxide or IMAC enrichment of phosphopeptides from cell or tissue lysates, followed by high‑resolution LC‑MS/MS (Orbitrap Fusion Lumos). Thousands of phosphorylation sites are identified and quantified (label‑free or TMT‑multiplex). This reveals the full landscape of signaling changes upon drug treatment, shRNA knockdown, or genetic mutation.

Phosphorylation stoichiometry (site‑specific occupancy) – Using parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM), we quantify the absolute or relative occupancy (percentage of molecules phosphorylated) at a given site. This requires isotope‑labeled heavy peptides as internal standards.

Phospho‑site mapping of a purified protein (by MS) – After in vitro kinase reaction, the target protein is digested and analyzed by LC‑MS/MS to determine which residues are phosphorylated. We also provide a semi‑quantitative estimate (high/medium/low confidence) of each site.

Site‑specific antibody validation – For a newly generated phospho‑specific antibody, we confirm specificity by Western blot using phospho‑site‑mutated lysates or by peptide array ELISA. We also determine the minimum detectable concentration of the phosphorylated peptide.

3. Standard Test Methods We Apply

All assays are performed according to established protocols and, where applicable, manufacturer‘s recommendations for commercial kits. Our laboratory is ISO/IEC 17025 accredited for biochemical and cellular assays (GLP compliance available).

3.1 Biochemical Kinase Assay Standards

Radiometric (³³P‑ATP / ³²P‑ATP) filter‑binding method: Traditional gold standard. The phosphorylated substrate is precipitated onto a filter membrane, unincorporated ATP is washed away, and radioactivity is counted (scintillation). Highly sensitive, any substrate can be used, no optical interference. Disadvantage: radioactive waste disposal.

IMAP (Immobilized Metal Affinity for Phosphochemicals) – Fluorescence polarization (FP)‑based. A terbium‑labeled anti‑phospho‑antibody binds to the phosphorylated peptide, and the change in fluorescence polarization is measured. Homogeneous, no wash steps. Suitable for high‑throughput screening (HTS).

Transcreener ADP detection – A far‑red fluorescent tracer binds to a custom antibody that recognizes ADP (not ATP). As ADP is generated, it displaces the tracer, causing a decrease in fluorescence polarization. Universal (since any kinase produces ADP), excellent for ATP‑competitive inhibitors.

ADP‑Glo (Promega) – Luminescent method. After kinase reaction, the remaining ATP is depleted; then ADP is converted to ATP, which is detected by luciferase/luciferin. Simple, homogenous, high signal‑to‑noise. Widely used for inhibitor screening.

Z’-LYTE / Adapta (Thermo Fisher) – FRET‑based. A proprietary peptide substrate contains a donor fluorophore (coumarin) and acceptor fluorophore (fluorescein). The phosphorylated peptide is recognized by a specific binding reagent, altering FRET. Fully automated, robust.

3.2 Cellular Phosphorylation Assay Standards

Western blot (immunoblotting): Standard method for semi‑quantitative detection of phosphoproteins. We use validated phospho‑specific antibodies (e.g., Cell Signaling Technology, Abcam, R&D Systems). Band densitometry relative to total protein loading control (GAPDH, tubulin, or total target protein).

ELISA (sandwich format): For high‑throughput quantification of a single phosphoprotein. We offer both commercial kits (e.g., R&D Systems DuoSet, Cisbio HTRF) and custom ELISAs. Detection by chemiluminescence or colorimetric methods. Lower LOD than Western blot.

Luminex xMAP (multiplex bead assay): Up to 50 phosphoproteins measured simultaneously from 25 μL of lysate. Each bead set has a unique spectral signature; detection is by PE‑conjugated secondary antibodies. Data presented as median fluorescence intensity (MFI).

AlphaLISA / AlphaScreen (PerkinElmer): Bead‑based homogeneous luminescence proximity assay. Donor and acceptor beads are brought together by the formation of the phosphoprotein‑antibody complex, generating a signal. High sensitivity, no wash, low sample volume (5‑10 μL).

Simple Western (Jess, Peggy Sue, Wes): Automated capillary western blot. Automates the entire Western blot workflow (separation, antibody binding, chemiluminescence detection). Produces quantitative, high‑reproducibility data with nanogram sample amounts. Ideal for precious clinical samples.

3.3 Phosphoproteomics & MS Standards

Phosphopeptide enrichment: IMAC (immobilized metal affinity chromatography – Fe³⁺‑NTA, Ga³⁺‑IMAC) or TiO₂ spin columns. We use high‑pH RP fractionation for deep coverage (≥10,000 phosphosites from mammalian cells).

LC‑MS/MS acquisition: Q‑Exactive HF‑X or Orbitrap Fusion Lumos equipped with EASY‑nLC 1200. Data‑dependent acquisition (DDA) with HCD fragmentation. For quantification, we use label‑free (MaxQuant, LFQ), TMT‑multiplex (10‑plex or 18‑plex), or targeted PRM (parallel reaction monitoring).

Data processing: MaxQuant or Proteome Discoverer for identification and quantification; phosphosite localization probability (≥0.75). Downstream analysis: differential expression (limma, DESeq2), motif analysis (MEME, motif‑x), kinase enrichment analysis (KSEA, iKiP).

4. Why Choose Our Third‑Party Phosphorylation Activity Testing Services?

As an independent laboratory, we provide unbiased, accurate, and actionable data. Our strengths include:

ISO/IEC 17025 accreditation – Our biochemical and cellular assay platforms are CNAS/CMA accredited, with regular participation in proficiency testing (e.g., NIST, EQAP).

Broad kinase panel – We offer access to over 500 purified kinases (full‑length, active) from commercial sources (SignalChem, Carna, Eurofins) and can work with custom kinase constructs provided by the client.

Multiple orthogonal assay formats – For IC₅₀ determination, we cross‑validate results using at least two different detection methods (e.g., ADP‑Glo and IMAP) to avoid compound interference (optical, aggregation).

Cell‑to‑MS integration – We bridge cell biology and proteomics: from drug treatment of cells to multiplex phosphoprotein analysis to deep phosphoproteomics – all under one roof.

Fast turnaround – Biochemical IC₅₀ (single kinase, 10‑point curve) completed within 1 week; cellular phosphorylation IC₅₀ (Western blot) within 2 weeks; phosphoproteomics (4‑condition TMT) within 3‑4 weeks.

Detailed reporting – For enzyme assays: IC₅₀ curve, K_m values, residual activity at top concentration. For cellular assays: dose‑response curves, EC₅₀, Western blot images with densitometry. For phosphoproteomics: list of phosphorylation sites (site localization, fold‑change, p‑value), volcano plots, kinase‑substrate network analysis.

Confidentiality – Full protection of compound structures, target lists, and proprietary research data.

Consultative support – Our signal transduction experts assist in experimental design (choice of substrate, ATP concentration, cell lines, stimulation/ starvation protocols), interpretation of cellular IC₅₀ vs. biochemical IC₅₀ discrepancies, and linkage of phosphoproteomics to pathway activation.

Whether you need to profile a kinase inhibitor’s selectivity across 100 kinases, measure the cellular potency of a PI3K inhibitor by p‑AKT ELISA, map the phosphorylation sites of a newly discovered kinase, or globally profile the phosphoproteome of a drug‑resistant cancer cell line, our phosphorylation activity assay experts are ready to deliver precise, reliable, and actionable results.

Get Started with Your Phosphorylation Activity Testing Project

Contact our team with your target kinase(s) (if known), assay type (biochemical, cellular, MS), sample type (purified protein, cells, tissue), and desired parameters (IC₅₀, selectivity panel, site mapping, global profiling). We will provide a detailed quotation, sample submission guidelines (cell number, lysate volume, compound handling), and a testing schedule. Let us help you unlock the secrets of cellular signaling with quantitative phosphorylation analysis.

This article provides an overview of our phosphorylation activity testing capabilities. For specific assays, sample quantity, and pricing, please request a tailored service proposal.